

Perspective. In the article “Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART” by Edward A. Berger, Bernard Moss, and Ira Pastan, which appeared in number 20, September 29, 1998, of *Proc. Natl. Acad. Sci. USA* (**95**, 11511–11513), it should be noted that the authors are co-inventors on patents covering the use of recombinant *Pseudomonas* exotoxin. The patents state that “A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.” The U.S. Patent Numbers are 5587455, 5428143, and 5206353.

Cell Biology. In the article “Activation of Ca²⁺ signaling in neutrophils by the mast cell-released immunophilin FKBP12” by Holger Bang, Wolfgang Müller, Michael Hans, Kay Brune, and Dieter Swandulla, which appeared in number 8, April 11, 1995, of *Proc. Natl. Acad. Sci. USA* (**92**, 3435–3438), the authors request the following correction. “The mast cells used for the experiments published in the above-mentioned publication were not HMC-1 cells but were most likely MC-9 cells from a mouse cell line.”

Developmental Biology. In the article “Derivation of pluripotent stem cells from cultured human primordial germ cells” by Michael J. Shambloott, Joyce Axelman, Shunping Wang, Elizabeth M. Bugg, John W. Littlefield, Peter J. Donovan, Paul D. Blumenthal, George R. Huggins, and John D. Gearhart, which appeared in number 23, November 10, 1998, of *Proc. Natl. Acad. Sci. USA* (**95**, 13726–13731), the following disclosure statement was inadvertently omitted: “Geron, Inc. provided funding for the study described in this article. Under a Licensing agreement between Geron and Johns Hopkins University, the University and Dr. Gearhart are entitled to a share of sales royalty from Geron. Both the University and Dr. Gearhart own stock in Geron, the sale of which is subject to certain restrictions under University policy. Dr. Gearhart is also a consultant to Geron. The terms of this arrangement are being managed by the University in accordance with its conflict of interest policies.”